10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer FC Hamdy, JL Donovan, JA Lane, M Mason, C Metcalfe, P Holding, ... New England Journal of Medicine 375 (15), 1415-1424, 2016 | 2938 | 2016 |
Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1695* | 2020 |
Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer JL Donovan, FC Hamdy, JA Lane, M Mason, C Metcalfe, E Walsh, ... New England Journal of Medicine 375 (15), 1425-1437, 2016 | 1333 | 2016 |
Multiple newly identified loci associated with prostate cancer susceptibility RA Eeles, Z Kote-Jarai, GG Giles, AAA Olama, M Guy, SK Jugurnauth, ... Nature genetics 40 (3), 316-321, 2008 | 1007 | 2008 |
Changes in circulating microRNA levels associated with prostate cancer RJ Bryant, T Pawlowski, JWF Catto, G Marsden, RL Vessella, B Rhees, ... British journal of cancer 106 (4), 768-774, 2012 | 832 | 2012 |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 781 | 2018 |
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array RA Eeles, AAA Olama, S Benlloch, EJ Saunders, DA Leongamornlert, ... Nature genetics 45 (4), 385-391, 2013 | 670 | 2013 |
Quality improvement report Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment … J Donovan, P Little, N Mills, M Smith, L Brindle, A Jacoby, T Peters, ... Bmj 325 (7367), 766-770, 2002 | 651* | 2002 |
Prevention and early detection of prostate cancer J Cuzick, MA Thorat, G Andriole, OW Brawley, PH Brown, Z Culig, ... The lancet oncology 15 (11), e484-e492, 2014 | 593 | 2014 |
Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients JC Carraro, JP Raynaud, G Koch, GD Chisholm, F Di Silverio, P Teillac, ... The Prostate 29 (4), 231-240, 1996 | 560 | 1996 |
MicroRNA in prostate, bladder, and kidney cancer: a systematic review JWF Catto, A Alcaraz, AS Bjartell, RDV White, CP Evans, S Fussel, ... European urology 59 (5), 671-681, 2011 | 559 | 2011 |
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ... Nature genetics 46 (10), 1103-1109, 2014 | 524 | 2014 |
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study RA Eeles, Z Kote-Jarai, AA Al Olama, GG Giles, M Guy, G Severi, K Muir, ... Nature genetics 41 (10), 1116-1121, 2009 | 487 | 2009 |
Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial RM Martin, JL Donovan, EL Turner, C Metcalfe, GJ Young, EI Walsh, ... Jama 319 (9), 883-895, 2018 | 447 | 2018 |
High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer C van den Hoogen, G van der Horst, H Cheung, JT Buijs, JM Lippitt, ... Cancer research 70 (12), 5163-5173, 2010 | 444 | 2010 |
Distinct microRNA alterations characterize high-and low-grade bladder cancer JWF Catto, S Miah, HC Owen, H Bryant, K Myers, E Dudziec, S Larré, ... Cancer research 69 (21), 8472-8481, 2009 | 400 | 2009 |
Multiple loci with different cancer specificities within the 8q24 gene desert M Ghoussaini, H Song, T Koessler, AA Al Olama, Z Kote-Jarai, KE Driver, ... JNCI: Journal of the National Cancer Institute 100 (13), 962-966, 2008 | 398 | 2008 |
Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1 S Ying, FC Hamdy, T Helleday Cancer research 72 (11), 2814-2821, 2012 | 376 | 2012 |
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells I Holen, PI Croucher, FC Hamdy, CL Eaton Cancer research 62 (6), 1619-1623, 2002 | 367 | 2002 |
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis AW Roddam, MJ Duffy, FC Hamdy, AM Ward, J Patnick, CP Price, ... European urology 48 (3), 386-399, 2005 | 364 | 2005 |